ASX ANNOUNCEMENT

31 August 2015

The Company Announcements Platform

ASX Limited

By E-lodgement

Intellectual Property Update – Two New Patents granted to Protect Lead Asset PTX-200

Melbourne, Australia, 31 August 2015: Prescient Therapeutics (ASX:PTX), a clinical stage oncology company, has substantially bolstered its intellectual property portfolio with two new US patents granted to protect its lead asset PTX-200.

The first patent, US Patent 9,101,641, covers Prescient's method for treating patients with tumours that overexpress AKT kinase, a key molecule in the oncogenic AKT signaling pathway.

Prescient's lead drug PTX-200 is a novel small molecule that works by blocking the AKT pathway, and inhibiting tumour growth.

High AKT expression is associated with a poor prognosis, resistance to chemotherapy and shortened survival times in a range of cancers. Trials of PTX-200 are currently underway in the United States in patients with breast and ovarian cancers.

Further expanding the company's IP portfolio is granted US Patent No. 9,115,162, which covers a proprietary method for identifying and treating a cancer patient with enhanced sensitivity to PTX-200 through a direct measurement of AKT levels in the patient's tumour. This patent further strengthens Prescient's focus on "personalised medicine" whereby patients are selected based on their tumour blueprint and treated with a specific drug that targets such blueprint, hence increasing the likelihood that a patient will respond to the drug. Personalized or tailored medicine is the way of the future, breaking the "one size fits all "approach to drug treatment that has seen many failures in the past.

Prescient's CEO, Dr Rob Crombie said these new patents further bolster an already-robust intellectual property portfolio and further enhance the PTX-200 value proposition.

"These latest patents further secure our monopoly rights over PTX-200 as we progress to fully exploit its potential in our ongoing clinical trials and as we move forward through to market."

About Prescient Therapeutics

Prescient Therapeutics is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. Department of Defense and U.S. National Cancer Institute. In addition, Prescient is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia in 2015.

Prescient's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways downstream of the cancer-casing protein Ras, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors. Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in 2015. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.

Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

Further Enquiries:

Dr Robert Crombie
Managing Director
+61 3 9982 4563

Paul Hopper
Executive Director
+61 406 671 515

Rudi Michelson
Monsoon Communications
+61 (0) 3 9620 3333